Ascendis Pharma - Public Comps and Valuation Multiples

Ascendis Pharma Overview

About Ascendis Pharma

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Founded

2006

HQ

Employees

1.0K+

Website

ascendispharma.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

Last FY Revenue $421M

Last FY EBITDA -$335M

EV

$12.8B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Ascendis Pharma Financials

See Ascendis Pharma valuation multiples based on analyst estimates

Ascendis Pharma P&L

In the most recent fiscal year, Ascendis Pharma reported revenue of $421M and EBITDA of -$335M.

Ascendis Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Ascendis Pharma valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$421M	XXX	XXX	XXX
Gross Profit	XXX	$369M	XXX	XXX	XXX
Gross Margin	XXX	88%	XXX	XXX	XXX
EBITDA	XXX	-$335M	XXX	XXX	XXX
EBITDA Margin	XXX	-80%	XXX	XXX	XXX
EBIT	XXX	-$322M	XXX	XXX	XXX
EBIT Margin	XXX	-77%	XXX	XXX	XXX
Net Profit	XXX	-$437M	XXX	XXX	XXX
Net Margin	XXX	-104%	XXX	XXX	XXX
Net Debt	XXX	$344M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Ascendis Pharma including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Ascendis Pharma achieved $421M in revenue and -$335M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$421M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$369M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	87.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	-$335M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	-79.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	-$322M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	-76.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	-$437M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	-104.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$344M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Ascendis Pharma

This financial data table provides comprehensive performance metrics for Ascendis Pharma, a company based in Germany. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Ascendis Pharma reported $421M in total revenue.
Fiscal year EBITDA was -$335M.
The company maintained a gross profit margin of 87.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was -79.8%.
Net profit margin reached -104.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Ascendis Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Ascendis Pharma Stock Performance

Ascendis Pharma has current market cap of EUR 10.8B (or $12.5B), and EV of EUR 11.1B (or $12.8B).

Market Cap Evolution

Ascendis Pharma Stock Data

As of October 17, 2025, Ascendis Pharma's stock price is EUR 179 (or $206).

See Ascendis Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$12.8B	$12.5B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Ascendis Pharma Valuation Multiples

Ascendis Pharma's trades at 30.5x EV/Revenue multiple, and -38.3x EV/EBITDA.

See valuation multiples for Ascendis Pharma and 15K+ public comps

Ascendis Pharma Financial Valuation Multiples

As of October 17, 2025, Ascendis Pharma has market cap of $12.5B and EV of $12.8B.

Equity research analysts estimate Ascendis Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Ascendis Pharma's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$12.5B	XXX	$12.5B	XXX	XXX	XXX
EV (current)	$12.8B	XXX	$12.8B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	30.5x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-38.3x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	-39.8x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	-28.6x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-36.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Ascendis Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Ascendis Pharma Margins & Growth Rates

Ascendis Pharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.7M for the same period.

Ascendis Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ascendis Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Ascendis Pharma and other 15K+ public comps

Ascendis Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-80%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.7M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	84%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	164%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial